Here are relevant reports on : cancer-diagnostics-market
-
Noninvasive Cancer Diagnostics Market by Instruments (Solid Tumor, Blood Cancer, Lung Cancer, Breast Cancer), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics) - Analysis & Global Forecast to 2019
The global non-invasive cancer diagnostic market is expected to show considerable growth during the forecast period. This is attributed to growing cancer cases worldwide, especially breast and lung cancer. In 2013, in the U.S. there were more than 1,660,290 new cases of all type of cancers diagnosed in 2013 (American Cancer Society). Increased healthcare expenditure and increase research and development activities are some of the other factors driving the growth of this market. However factors such as high cost of treatment, and stringent regulatory guidelines are limiting the market growth.
- Published: December 2026
- Price: $ 4950
- TOC Available:
-
Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031
The global cancer diagnostics market is projected to reach USD 44.92 billion by 2031, growing at a CAGR of 7.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2032
The global cancer biomarkers market is projected to reach USD 54.48 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2026–2032). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: May 2026
- Price: $ 7150
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2030
The global Tissue Diagnostics market, valued at USD 6.19 billion in 2024, stood at USD 6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of USD10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application (Infectious, Cancer), Technique, Clinical Application, End User- Global Forecast to 2031
The molecular diagnostics market is estimated at USD 21.68 billion in 2026 and is projected to reach USD 32.56 billion by 2031 at a CAGR of 8.5% during the forecast period. The Key Players Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Limited (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Immuno Oncology Assays Market Size, Share & Trends by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026
The size of global immuno oncology assays market in terms of revenue was estimated to be worth USD 4.4 billion in 2021 and is poised to reach USD 7.9 billion by 2026, growing at a CAGR of 12.5% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030
The global immunohistochemistry market, valued at US$3.31 billion in 2024, stood at US$3.55 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of US$5.14 billion by the end of the period. The increasing number of cancer cases is one of the key factors driving the uptake of IHC products, which, in turn, leads to a greater need for accurate and efficient diagnostic tools such as IHC tests.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Womens Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care) & Region - Global Forecast to 2025
The global womens health diagnostics market growth is primed to transition from $25.0 billion in 2020 to $36.6 billion by 2025, showcasing a strong CAGR of 7.9%. The market growth is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.
- Published: February 2021
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
